LOCALLY ADVANCED SOLID TUMOR

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This study tests a new drug called neladalkib (NVL-655) in people with advanced ALK-positive non-small cell lung cancer and other solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well it shrinks tumors. Up to 840 participants will be en…

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This early-phase study tests a new oral drug, NVL-330, in about 200 adults with advanced or metastatic non-small cell lung cancer that has specific HER2 mutations. The goal is to find the safest and most effective dose and see if the drug can shrink tumors. Participants must have…

This study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can s…

This study tests a new drug called zidesamtinib (NVL-520) for people with advanced lung cancer or other solid tumors that have a specific genetic change (ROS1-positive). The goal is to find the best dose and see how well it shrinks tumors. About 359 adults will take part in two p…

This study tests a special imaging agent (89Zr-DF-Crefmirlimab) that helps PET scans show immune cells called CD8 T-cells inside tumors. About 30 adults with advanced solid tumors will receive this agent before and during standard immunotherapy (anti-PD-1). The goal is to see if …

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …